No Data
No Data
Analysts Have Been Trimming Their Apyx Medical Corporation (NASDAQ:APYX) Price Target After Its Latest Report
Apyx Medical | 10-Q: Quarterly report
Apyx Medical (APYX.US): The 2024 Q1 financial report achieved revenue of US$10.244 million, previous value of US$12.142 million, expected value of US$9.53 million; earnings per share were -0.22 USD, previous value was -0.10 USD, and expected value was -0.
Apyx Medical (APYX.US): The 2024 Q1 financial report achieved revenue of US$10.244 million, previous value of US$12.142 million, expected value of US$9.53 million; earnings per share were -0.22 USD, previous value was -0.10 USD, and expected value was -0.21 USD.
Apyx Medical Sees FY24 Revenues Of $49.7M-$52.9M Vs. $49.94M Estimate, Representing Decrease Of Approximately 5% Compared To Growth Of Approximately 1% YoY
Apyx Medical Sees FY24 Revenues Of $49.7M-$52.9M Vs. $49.94M Estimate, Representing Decrease Of Approximately 5% Compared To Growth Of Approximately 1% YoY
Apyx Medical Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $10.24M Beat $9.53M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 120 percent decrease over losses of $(0.10)
Apyx Medical 1Q Loss/Shr 22c >APYX
Apyx Medical 1Q Loss/Shr 22c >APYX